← All institutions

Barclays

17 reports

Reports from this institution

Barclays

Barclays: Merck’s personalized cancer vaccine phase III data: Clear recurrence benefit, but commercial potential still depends on durability

INT combined with Keytruda increased the two-year recurrence-free survival rate in melanoma patients by 12.2 percentage points, but the distant metastasis benefit was weaker than in phase II, and overall survival data remain immature. Barclays sees substantial room in postoperative adjuvant treatment and maintains its Overweight rating on Merck.

Barclays

Barclays: Chinese tech companies’ AI investment faces a financing test: Baidu’s gap is most imminent, while Tencent has stronger cash flow

Alibaba and Tencent’s combined capital expenditure in a single quarter was approximately 120 billion yuan. AI commercialization is accelerating, but most companies remain in the investment phase. Barclays expects Baidu to be the most likely to need additional financing over the next 15 months, while Alibaba’s potential gap would emerge later.

Barclays

Barclays: Bank of Japan expected to pause rate hikes in October, inflation assessment could pave the way for December

Barclays expects the Bank of Japan to keep its policy rate at 1.25% in October while upgrading its assessment of underlying inflation to broadly consistent with the 2% target. Financial conditions remain accommodative, supporting subsequent rate hikes every three to four months, but weaker domestic demand and a subsequent decline in inflation limit the room for tightening.